{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-23-000103","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.794018+00:00","generated_at":"2026-06-11T15:29:23.685083+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Senti Bio extends cash runway into Q4 2024 via GeneFab deal, Q2 net loss $18.7M","bullets":["GeneFab transaction provides up to $38M in cash by end of 2025; extends cash runway into Q4 2024.","IND for SENTI-202 (Logic Gated CAR-NK for AML) on track for 2H 2023; Phase 1 enrollment expected 2024.","Cash, equivalents & short-term investments $59.6M as of June 30, 2023.","Q2 net loss $18.7M ($0.42/share); R&D $11.0M (up from $9.2M), G&A $9.6M (down from $13.9M).","Senti subleases Alameda cGMP facility to GeneFab; co-founder Philip Lee named GeneFab CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-23-000103","json":"https://secwatch.observer/filing/0001854270-23-000103.json","markdown":"https://secwatch.observer/filing/0001854270-23-000103.md","text":"https://secwatch.observer/filing/0001854270-23-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000103/0001854270-23-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000103/snti-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:29:23.685083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2396b53df53e896917c36f80c0b2b49b36d8002","claim":"Senti Biosciences, Inc. reported financial results for quarter ended June 30, 2023.","evidence_excerpt":"On August 11, 2023, Senti Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000103/0001854270-23-000103-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}